What does Pegloticase (Krystexxa) do in plain English—and how does it work inside your body?
Pegloticase is an FDA-regulated Uric Acid-specific Enzyme (RxNorm RxCUI RXN-75987058-2264). Mechanistically, Upon intravenous-route administration of 8 mg/50mL Injection, Solution and 8 mg/mL Injection, Solution, Pegloticase (manufactured/labeled by Horizon Therapeutics USA, Inc.; NDC 75987-058, 75987-080) engages uric acid-specific enzyme biochemical pathways to achieve steady-state therapeutic response balanced against organ-specific metabolic elimination. [1][2].
When your doctor writes a prescription for Pegloticase (RxNorm RxCUI RXN-75987058-2264, also dispensed under brand names including Krystexxa), the goal is to target the root physiological pathway driving your condition rather than just masking surface symptoms [1]. According to the official FDA DailyMed package insert, Upon intravenous-route administration of 8 mg/50mL Injection, Solution and 8 mg/mL Injection, Solution, Pegloticase (manufactured/labeled by Horizon Therapeutics USA, Inc.; NDC 75987-058, 75987-080) engages uric acid-specific enzyme biochemical pathways to achieve steady-state therapeutic response balanced against organ-specific metabolic elimination. [2].
Across real-world patient logs on dotMD (84% positive worth-it rating), patients do best when they understand both what the medication is doing on day 1 and how long it takes to reach steady-state protection [3].
Check the imprint code on your Pegloticase tablet bottle and confirm with your pharmacist that it matches your prescribed strength (8 mg/50mL Injection, Solution, 8 mg/mL Injection, Solution).